Key result
A doubling of admission MR-proADM concentration in patients with STEMI was associated with increased long-term mortality (HR 3.23; 95% CI 1.97-5.29; P<0.0001).
Why the study?
Does admission MR-proADM concentration predict mortality and heart failure admission in patients with STEMI?
Cohort (n=1,122)
Does admission MR-proADM concentration predict mortality and heart failure admission in patients with STEMI?
Hazard Ratio: 3.23 (95% CI 1.97–5.29)
p-value: p=<0.0001
While elevated admission MR-proADM is associated with long-term mortality and heart failure in STEMI patients, it does not add substantial prognostic value to established clinical models.
No takes yet. Share an insight, caveat, or question.
Elevated MR-proADM signals higher STEMI mortality yet adds little to clinical models; leaves open prospective validation for risk stratification.
Falkentoft et al. (2018) conducted a cohort in ST-segment-elevation myocardial infarction (n=1,122). MR-proADM was evaluated on Long-term mortality (HR 3.23, 95% CI 1.97-5.29, p=<0.0001). A doubling of admission MR-proADM concentration in patients with STEMI was associated with increased long-term mortality (HR 3.23; 95% CI 1.97-5.29; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: